Gary Altwerger

Yale University — United States

Medicine · Health Sciences

28h-index2.0kcitations165works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(43), HER2/EGFR in Cancer Research(26), Endometrial and Cervical Cancer Treatments(21), Uterine Myomas and Treatments(21), Protein Degradation and Inhibitors(21)

Publications165 total

Oncologically safe minimally invasive management of a 25 cm cystic abdominopelvic mass using contained, controlled drainage and removal
Gynecologic Oncology Reports·2026Open Access
The Role of Omental Sampling in Staging High Grade Uterine Carcinoma
SSRN Electronic Journal·2026Open Access
Response to Correspondence on “Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective two-center cohort study”
International Journal of Gynecological Cancer·2026
Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study
International Journal of Gynecological Cancer·2025· 2 cited
HIPEC with cisplatin desensitization at the time of secondary debulking in a patient with a prior carboplatin hypersensitivity reaction
Gynecologic Oncology Reports·2025Open Access
A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER
International Journal of Gynecological Cancer·2025
Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case
Gynecologic Oncology Reports·2025· 1 citedOpen Access
Datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma
Gynecologic Oncology·2025
Role of systematic lymphadenectomy at the time of cytoreductive surgery among non-high grade serous epithelial ovarian cancers
Gynecologic Oncology·2025
Retrospective analysis of lenvatinib and pembrolizumab in endometrial cancer: Efficacy by tumor characteristics, platinum status and lenvatinib dose
Gynecologic Oncology·2025
In vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma
Gynecologic Oncology·2025
Uterine teratoma and the role of short-tandem repeat genotyping in understanding origins
Gynecologic Oncology Reports·2024· 2 citedOpen Access
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses
Gynecologic Oncology·2024
Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients
PLoS ONE·2024· 8 citedOpen Access
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Clinical & Experimental Metastasis·2024· 9 cited
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
BJC Reports·2024Open Access
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum- resistant or refractory ovarian / fallopian tube / primary peritoneal cancer (NCT03093155): updated survival and subgroup analyses
Research Square (Research Square)·2024· 1 citedOpen Access
Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail
International Journal of Gynecological Cancer·2024Open Access
Conventional laparoscopic resection of platinum-sensitive recurrent oligometastatic ovarian cancer lesion in the interaortocaval region
International Journal of Gynecological Cancer·2024Open Access
Supplementary Data S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
2024Open Access
page 1 of 9Next →

Frequent Co-authors

Elena Ratner(44), Alessandro D. Santin(43), Masoud Azodi(42), Peter E. Schwartz(40), Stefania Bellone(34), Gulden Menderes(33), Gloria S. Huang(33), Pei Hui(27), Natália Buza(25), Elena Bonazzoli(23), Dan‐Arin Silasi(22), Luca Zammataro(21), Vaagn Andikyan(19), Mitchell Clark(19), Burak Zeybek(18), Salvatore Lopez(17), Joan Tymon‐Rosario(16), Justin Harold(16), Chanhee Han(15), Aránzazu Manzano(13)